Atara shares soar after beating analyst estimates
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Biotech giant Amgen bails on brain research
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen buying 20 percent of BeiGene for $2.7 billion
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen earnings beat expectations
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen cuts list price of Repatha by 60 percent
Amgen doubled down on its decision to slash the list price of one of its newest drugs, Repatha, listing it for all patients at $5,840 per year. The Thousand Oaks-based biotech giant reduced the list price by 60 percent for some patients for the cholesterol medication a year before, and the announcement Oct. 24 discontinues Read More →
Read More →Amgen warns investors of ‘mini-tender’ offer
Biotech giant Amgen warned investors of a so-called “mini-tender” offer by TRC Capital Corp. that seeks to buy half a million of the company’s shares at below-market prices ahead of its third quarter earnings. The unsolicited offer is dated Oct. 11 and offers to purchase up to 500,000 of Amgen common stock at $192 per Read More →
Read More →Teledyne shares soar as earnings beat estimates
Shares of Thousand Oaks-based Teledyne Technologies jumped nearly 6 percent or $18 on Oct. 23 after the company reported quarterly results that beat estimates. Teledyne shares were trading in the $330 range in afternoon trading after the company reported adjusted earnings of $2.57 per share and revenue of $802.20 million for the quarter ended September Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
